Engerix B 10micrograms/0.5ml vaccine suspension for injection vials

Šalis: Didžioji Britanija

kalba: anglų

Šaltinis: MHRA (Medicines & Healthcare Products Regulatory Agency)

Veiklioji medžiaga:

Hepatitis B virus surface antigen

Prieinama:

GlaxoSmithKline UK Ltd

ATC kodas:

J07BC01

INN (Tarptautinis Pavadinimas):

Hepatitis B virus surface antigen

Dozė:

20microgram/1ml

Vaisto forma:

Suspension for injection

Vartojimo būdas:

Intramuscular; Subcutaneous

Klasė:

No Controlled Drug Status

Recepto tipas:

Valid as a prescribable product

Produkto santrauka:

BNF: 14040000

Pakuotės lapelis

- 1 -
PACKAGE LEAFLET: INFORMATION FOR THE USER
ENGERIX B
®
20 MICROGRAMS/1 ML SUSPENSION FOR INJECTION
Hepatitis B (rDNA) vaccine (adsorbed) (HBV)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START RECEIVING THIS
VACCINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This vaccine has been prescribed for you only. Do not pass it on to
others.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1 What Engerix B is and what it is used for
2 What you need to know before you receive Engerix B
3 How Engerix B is given
4 Possible side effects
5 How to store Engerix B
6 Contents of the pack and other information
1
WHAT ENGERIX B IS AND WHAT IT IS USED FOR
Engerix B is a vaccine used to prevent hepatitis B infection. It can
also help to prevent
hepatitis D infection.
This vaccine can be given to both adults and adolescents 16 years of
age and over. In
exceptional circumstances it can also be given to children and
adolescents 11 to 15 years of
age (see section 3).
Hepatitis B is an infectious illness of the liver caused by a virus.
Some people have the
hepatitis B virus in their body but cannot get rid of it. They can
still infect other people and
are known as carriers. The disease is spread by the virus entering the
body following
contact with body fluids, most often blood, from an infected person.
If the mother is a carrier of the virus she can pass the virus to her
baby at birth. It is also
possible to catch the virus from a carrier through, for example,
unprotected sex, shared
injection needles or treatment with medical equipment which has not
been properly
sterilised.
The main signs of the illness include headache, fever, sickness and
jaundice (yellowing of
the skin and eyes) but in about three out of 10 patients there are no
signs of illness.
In those infected wi

Prekės savybės

OBJECT 1
ENGERIX B 20 MICROGRAMS/1 ML VIALS
Summary of Product Characteristics Updated 24-Apr-2017 |
GlaxoSmithKline UK
1. Name of the medicinal product
Engerix B® 20 micrograms/1 ml
Suspension for injection
Hepatitis B (rDNA) vaccine adsorbed (HBV)
2. Qualitative and quantitative composition
1 dose (0.5 ml) contains :
Hepatitis B surface antigen
1,2
, 10 micrograms
1
Adsorbed on aluminium hydroxide, hydrated Al
3+
Total: 0.25 milligrams
2
Produced in yeast cells (_Saccharomyces cerevisiae_) by recombinant
DNA technology
1 dose (1 ml) contains :
Hepatitis B surface antigen
1,2
, 20 micrograms
1
Adsorbed on aluminium hydroxide, hydrated Al
3+
Total: 0.50 milligrams
2
Produced in yeast cells (_Saccharomyces cerevisiae_) by recombinant
DNA technology
For the full list of excipients, see section 6.1
3. Pharmaceutical form
Suspension for injection.
The suspension is turbid white.
4. Clinical particulars
4.1 Therapeutic indications
Engerix B is indicated for active immunisation against hepatitis B
virus infection (HBV) caused by all
known subtypes in non immune subjects. The 20 µg dose vaccine in 1.0
ml suspension is intended for use
in subjects 16 years of age and above. The 10 µg dose vaccine in 0.5
ml suspension is intended for use in
subjects up to and including 15 years of age, including neonates. The
categories within the population to
be immunised are determined on the basis of official recommendations.
It can be expected that hepatitis D will also be prevented by
immunisation with Engerix B as hepatitis D
(caused by the delta agent) does not occur in the absence of hepatitis
B infection.
4.2 Posology and method of administration
_Posology _
_Dosage_
The 20 µg dose vaccine in 1.0 ml suspension is intended for use in
subjects 16 years of age and above.
The 10 µg dose vaccine in 0.5 ml suspension is intended for use in
subjects up to and including 15 years
of age, including neonates.
However, the 20 µg vaccine can also be used in subjects from 11 years
up to and including 15 years of
age as a 2-dose schedule